Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 13/20 | 0.35 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2131156 | 1.00 | AAK1 (0.35) | AAK1MRGPRX4PTGDR2EGFRIDO1 | |
| SCHEMBL3695441 | 0.91 | AAK1 (0.33) | AAK1MRGPRX4 | |
| SCHEMBL2130605 | 0.90 | AAK1 (0.33) | AAK1MRGPRX4 | |
| SCHEMBL2130607 | 0.90 | MRGPRX4 (0.34) | AAK1MRGPRX4 | |
| SCHEMBL2131508 | 0.90 | PTGDR2 (0.33) | AAK1MRGPRX4PTGDR2EGFRIDO1 | |
| SCHEMBL2131502 | 0.90 | PTGDR2 (0.33) | AAK1MRGPRX4PTGDR2EGFRIDO1 | |
| SCHEMBL2128848 | 0.90 | MRGPRX4 (0.33) | AAK1MRGPRX4PTGDR2EGFRIDO1 | |
| SCHEMBL2128839 | 0.90 | MRGPRX4 (0.33) | AAK1MRGPRX4PTGDR2EGFRIDO1 | |
| SCHEMBL2129421 | 0.89 | AAK1 (0.37) | AAK1IDO1 | |
| SCHEMBL2129427 | 0.89 | AAK1 (0.37) | AAK1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2452944-B1 | DIPHENYL SULFIDE DERIVATIVES AND MEDICINES CONTAINING THEM AS ACTIVE INGREDIENT | KYORIN SEIYAKU KK (JP) | 2014-09-10 | — | — | EP | disclosed |
| US-8569270-B2 | Diphenyl sulfide derivatives and medicines containing same as active ingredient | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2013-10-29 | — | — | US | disclosed |
| EP-2452944-A1 | DIPHENYL SULFIDE DERIVATIVES AND MEDICINES CONTAINING SAME AS ACTIVE INGREDIENT | Kyorin Pharmaceutical Co., Ltd. (JP) | 2012-05-16 | — | — | EP | disclosed |
| US-20120101068-A1 | DIPHENYL SULFIDE DERIVATIVES AND MEDICINES CONTAINING SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101068-A1 | DIPHENYL SULFIDE DERIVATIVES AND MEDICINES CONTAINING SAME AS ACTIVE INGREDIENT | S1PR3, S1PR1, S1PR2 | AAK1 3218/4885MRGPRX4 62/4885PTGDR2 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.